(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Generative AI in Clinical Trials - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global generative AI in clinical trials market was valued at US$237.2 billion in 2025 and is projected to reach US$964.2 billion by 2032, expanding at a compound annual growth rate (CAGR) of 22.2%. Growth is being supported by increased adoption of adaptive trial design, AI-enabled patient recruitment, synthetic clinical data, predictive safety monitoring and decentralized clinical trial models.
Adaptive, Data-Guided Clinical Trial Design
Clinical development is moving from fixed protocols toward adaptive strategies that analyze historical and real-time study data. Generative AI models can simulate protocol configurations, evaluate enrollment scenarios and identify study structures designed to improve statistical power while reducing unnecessary participant exposure.
Researchers are using these capabilities to assess recruitment feasibility across regions and demographic groups, refine eligibility criteria using electronic health records and model dosing strategies based on early treatment responses. AI-generated dropout forecasts can also help investigators adjust cohort sizes, while predictive site-selection models assess investigator experience, patient availability and expected operational performance.
Continuous-learning systems further support clinical operations by updating trial parameters as real-world evidence becomes available. When validated within predefined statistical and regulatory frameworks, these approaches can reduce protocol amendments, improve resource allocation and shorten development timelines.
AI-Enabled Patient Recruitment and Retention
Patient recruitment remains a major operational challenge in clinical research. Generative AI platforms can analyze medical records to identify eligible participants and develop targeted outreach strategies based on patient characteristics, treatment history and location.
Additional applications include multilingual communication, personalized follow-up schedules, digital consent materials and engagement prompts informed by wearable-device data. Predictive models can identify participants at elevated risk of withdrawal, allowing trial coordinators to intervene earlier. Travel-burden analysis can also support site allocation and decentralized trial planning, helping sponsors improve accessibility, participant diversity, retention and study completion rates.
Synthetic Clinical Data and Predictive Development Models
Synthetic clinical datasets are increasingly being used to test hypotheses, evaluate endpoint sensitivity and model treatment-response variability before human enrollment. Drug developers can apply generative AI to pharmacokinetic and pharmacodynamic modeling, adverse-event simulations, biomarker discovery and virtual patient models.
These tools can strengthen early-stage decision-making, test safety-detection systems and reduce uncertainty before studies begin. Synthetic evidence complements clinical and real-world data but remains subject to validation, governance, privacy and regulatory requirements.
Primary Market Growth Drivers
Demand for shorter and more efficient clinical trial timelines Increased use of electronic health records for patient identification Expansion of adaptive and decentralized clinical trial models Growing demand for predictive safety monitoring Rising adoption of biomarker- and genomics-driven therapies Integration of wearable and remote-monitoring data Pressure to reduce the financial impact of late-stage trial failure Improved availability of multimodal healthcare datasets Regulatory interest in transparent, data-driven study design
Market Segmentation and Geographic Coverage
The report analyzes the generative AI in clinical trials market by technology, application, end user and geography.
Technology: Variational autoencoders, generative adversarial networks, deep convolutional networks, transfer learning and other technologies Application: Data generation, clinical trial design, outcome prediction, adverse-event detection and other applications End User: Researchers and scientists, clinical trial sponsors and contract research organizations, and other end users Geography: United States, Canada, Japan, China, France, Germany, Italy, United Kingdom, the rest of Europe, Asia-Pacific and the rest of the world
Key Market Insights
The variational autoencoders segment is projected to reach US$253 billion by 2032, expanding at a CAGR of 19.5%. The generative adversarial networks segment is forecast to grow at a CAGR of 22% during the analysis period. The U.S. market was valued at US$70.8 billion in 2025. China is projected to expand at a CAGR of 21.2% and reach US$163.6 billion by 2032. Additional growth opportunities are assessed across Japan, Canada, Germany, Europe and Asia-Pacific.
Report Benefits
Independent annual market analysis and forecasts from 2025 through 2032 Detailed evaluation of technologies, applications, end users and regional markets Competitive intelligence covering major participants and geographic market presence Analysis of trends, growth drivers, restraints and emerging revenue opportunities Strategic insights to support investment, commercialization and market-entry decisions Company profiles and one year of complimentary report updates
Companies Featured
Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. Google LLC IBM Corporation Johnson & Johnson Services, Inc. Microsoft Corporation Neuralink Novartis AG NVIDIA Corporation Oracle Corporation
Domain Expert Insights
The analysis incorporates perspectives from experts across industry, enterprise and academia, adding strategic context to established market research. The report tracks early market signals emerging from expert discussions, corporate activity, conferences, keynote presentations, panel sessions, company disclosures, annual reports and institutional publications.
These inputs are evaluated against a broad, validated intelligence base to identify changes in market direction, competitive positioning and technology adoption. The report also extends beyond market-level analysis to examine companies influencing the competitive environment.
Market share is assessed where it provides meaningful strategic value. Because competitive structures vary by geography, regional market-share analysis is included where relevant and tailored to the characteristics of each market.
Key Questions Addressed
How will the global generative AI in clinical trials market evolve through 2032? Which technologies and applications are expected to record the strongest growth? What factors are driving or restraining market adoption? How will regional and segment-level market positions change? Which companies are shaping the competitive landscape? Where are the most significant strategic and revenue opportunities emerging?
Key Attributes
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment